Oncology

Suppression of Wnt signaling pathway shows promise.

Re-engineering antibodies allows them to selectively kill tumors.

Pfizer seeking to expand approved use of Xalkori to patients with ROS1-positive non-small cell lung cancer.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.

Researchers determine mechanism for poor survival rates in African American patients with estrogen-receptor positive breast cancer.

Mild exercise found to improve fatigue and depression.

Mild cognitive impairment can set in prior to the start of therapy.

Selumetinib treats a rare disease where cancer cells form within eye tissues.

Itraconazole shows some promise in treatment of metastatic prostate cancer.

Study showed a median overall survival of nearly 3 years with Zytiga plus prednisone.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses how specialty pharmacists can help manage difficult lung cancer therapy.

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

Study suggests substances in synthetic marijuana may damage human cell DNA.

Spat occurs with customer picking up cancer medication.

Abiraterone acetate (Zytiga) significantly prolongs survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Treatment will be available for clinical trials in patients with certain types of leukemia and non-Hodgkin lymphomas later this year.

Combination of nintedanib with docetaxel primarily depends on whether patients already had brain metastases.

Supplements containing creatine or androstenedione significantly increase disease risk.

Liquid bendamustine hydrochloride rapid infusion treats patients with chronic lymphocytic leukemia.

Low temperature plasmas found to induce high levels of DNA damage.

Specialty pharmacists are instrumental in addressing the particular needs of patients undergoing highly specialized cancer treatments.

Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.

Longer telomeres gives cancer cells a survival advantage.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses innovative new therapies for the treatment of cancer.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Analysis of cancer-causing mutations in the BRCA1 or BRCA2 genes may lead to more effective treatments.

Study finds that UV tanning meets the same criteria as smoking as a cause of cancer.